Syngene International Limited , a leading contract research organization, has announced a significant addition to its leadership team. Effective October 28, 2025, Surender Sharma will join the company as General Counsel and member of the Executive Committee, bringing over two decades of extensive experience in corporate governance and legal affairs.

Key Appointment Details

Professional Background

Sharma joins Syngene from Colgate-Palmolive (India) Limited, where he most recently held the position of Whole-Time Director and Vice President — Legal, Secretarial, and Corporate Affairs. His impressive career spans several renowned organizations, including:

• Colgate-Palmolive
• Marico
• Heinz
• Indian Hotels
• Reckitt
• Maruti

Areas of Expertise

Sharma's extensive experience covers crucial areas in corporate legal affairs:

• Corporate governance
• Mergers and acquisitions
• Joint ventures
• Compliance
• Regulatory affairs

Throughout his career, Sharma has successfully navigated complex legal and governance matters, advised Boards and leadership teams on risk and compliance, and played a pivotal role in developing and strengthening corporate ethics and sustainability frameworks.

Educational Background

Sharma's educational qualifications underscore his multidisciplinary expertise:

This appointment comes as Syngene International continues to strengthen its leadership team. Sharma's diverse experience across multiple industries and his strong educational background are likely to bring valuable insights to Syngene's executive decision-making process.

As the company navigates the complex landscape of contract research and development, Sharma's expertise in corporate governance, compliance, and regulatory affairs could prove instrumental in maintaining Syngene's competitive edge while ensuring adherence to legal and ethical standards.

Syngene International , a leading contract research organization, has announced plans to enhance its biologics capabilities by introducing antibody-drug conjugate (ADC) bioconjugation services at its facility. This strategic expansion aims to provide comprehensive, end-to-end solutions for ADCs, spanning from discovery to GMP manufacturing.

Key Highlights of the Expansion

• Integrated Services: Syngene will offer fully integrated services for ADCs, covering the entire development process from discovery to GMP manufacturing.
• Single-Site Efficiency: The new capability enables both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single location, potentially accelerating development timelines.
• Complementary Capabilities: This addition complements Syngene's existing commercial expertise in payload and linker manufacturing.

Business Impact and Regulatory Perspective

Syngene has clarified that this investment in bioconjugation capabilities is part of its ordinary course of business. According to the company's statement to the stock exchanges:

• The expansion does not meet the materiality criteria as specified under the Industry Standards Note (ISN) on Regulation 30 of the SEBI Listing Regulations.
• It is not deemed 'material' as per the current specifications under SEBI Listing Regulations.

Implications for the Biopharma Industry

This expansion by Syngene International could have significant implications for the biopharmaceutical industry:

1. Streamlined Development: The integration of mAb production and GMP bioconjugation at a single site may lead to more efficient ADC development processes.
2. Enhanced Capabilities: Syngene's expanded services could attract more clients in the growing ADC market, potentially strengthening its position in the contract research and manufacturing space.
3. Innovation Support: The end-to-end ADC services could facilitate faster progression of novel therapies from discovery to clinical trials.

While the financial details of this expansion have not been disclosed, the move aligns with the growing demand for ADC development and manufacturing services in the global biopharmaceutical market.

Investors and industry observers may monitor how this expansion impacts Syngene's service offerings and market position in the coming months. As always, stakeholders are advised to consider multiple factors and consult financial advisors before making investment decisions based on corporate developments.